
LH Stock Forecast & Price Target
LH Analyst Ratings
Bulls say
Labcorp Holdings has demonstrated strong revenue growth, with its Central Lab segment achieving $554.7 million, reflecting a 7.5% increase, attributed to significant trial wins and advancements in digital pathology supported by AI. The company has an impressive backlog of $8.71 billion, marking a year-over-year increase of approximately 10%, alongside a trailing twelve-month net book-to-bill ratio of 1.11x, indicating robust future demand for its services. In the Diagnostic segment, Labcorp reported revenue of $2.75 billion, up 8.9% year-over-year, driven by balanced contributions from both organic growth and acquisitions, showcasing a strong operational performance.
Bears say
Labcorp Holdings faces significant risks that may adversely impact its financial performance, including potential adverse shifts in reimbursement policies under the Protecting Access to Medicare Act (PAMA) and challenges stemming from the integration of acquisitions. The company also encounters pressures from economic uncertainties and increased competition, which may further strain its market position. Additionally, regulatory challenges related to laboratory-developed tests (LDTs) could pose further threats to Labcorp's operational stability and profitability.
This aggregate rating is based on analysts' research of Labcorp Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
LH Analyst Forecast & Price Prediction
Start investing in LH
Order type
Buy in
Order amount
Est. shares
0 shares